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Abstract
The current standard of care in glioblastoma management
is surgery followed by chemotherapy and radiotherapy.
Temozolomide is an alkylating agent most commonly used
with a few other second line options. The efficacy of
systemic chemotherapy in brain malignancies is limited
due to the nature of the blood-brain barrier. Nanomedicine
offers one avenue of improving drug delivery to these
tumours in a more focussed and effective way in higher
doses than currently possible, while simultaneously
reducing systemic toxicity.
Keywords: Glioblastoma multiforme, brain tumour,
nanotechnology
Introduction
Glioblastoma (GBM), is a WHO grade IV pathology and has
a dismal prognosis.1 Despite advances in treatment, the
current therapy based primarily on surgical resection with
adjuvant chemotherapy and radiotherapy offers modest
temporary disease control.2 The blood-brain barrier (BBB)
is a formidable impediment to drug delivery in the brain
which limits the promise of effective chemotherapy in vivo.
Nanomedicine offers a unique promise of more precise
drug delivery with several options currently under
investigation.
Review of literature
Nanoparticles (NPs) are natural, incidental or manufactured
materials composed of particles ranging between 1 nm
and 100 nm in size. NPs are being investigated as an
alternative approach in anticancer therapies in order to
improve targeted drug delivery, reduce side effects and
avoid drug toxicity and resistance.3 The strategy can
actively transport small molecular drugs, gene medicines
and therapeutic proteins to specific tumours including the
commonest primary malignant brain tumour, glioblastoma
multiforme (GBM). In order to achieve therapeutic targets,
drug delivery systems should exhibit high drug loading
capacity, good biocompatibility and  biodegradability
profiles, effective tumour penetration, enhanced cellular
internalization, controlled drug release and the ability to
evade mononuclear phagocytic system so as to avoid
premature degradation of drugs.4
Treatment of malignant brain tumours, particularly GBM is
a significant challenge. (Figure). Current GBM therapy is a
combination of surgery, radiotherapy and chemotherapy,
occasionally coupled with anti-VEGF (Bevacizumab)
therapy but since these have been unable to achieve
disease control beyond 14-18 months, a constant search
for new treatments with improved efficiency and less
adverse effects is underway.5 In an effort to bypass the BBB,
high tumour heterogeneity, genetic mutations, active
efflux transporters and GBM induced immunosuppression,
targeted nanotherapeutics have shown potential to
improve pharmacokinetic profile and therapeutic efficacy
of drugs as they can be designed to have many favourable
characteristics which aid preferential delivery of
therapeutic molecules directly to the tumour.6-9 There is
data to support the notion that the efficacy of
nanoparticles in GBM is governed by physical and chemical
properties of nanomaterials, including  their size, shape,
surface area, chemistry, charge, functional groups and
concentrations as well as nano-biointeractions. In general,
smaller sized (<50nm) anionic particles are a more viable
option for successful delivery to GBM especially in early
disease stages due to their inverse relation to BBB
permeability.6 Shape is important for internalization, cell
viability and to attain a longer half-life. The most common
shape is spherical, although other shapes such as rods, may
be advantageous to avoid immune clearance. NPs for GBM
are usually administered intravenously but the intranasal
route may be considered as an alternative as it is less
invasive and more rapid in action. Other routes such as
intra-cranial or intra-tumoural may carry a higher risk of
infection and toxicity to healthy neurons.6 Surface
modification compounds such as polyethylene glycol (PEG)
derivatives are commonly used to improve NPs stability
and reduce opsonization and interaction with protein
corona of blood.9 This is crucial to attain a half-life long
enough for the NPs to reach the target site. Several agents
other than PEG, however, are being analyzed because of
the development of anti-PEG antibodies.10
Accumulation of NPs at tumour site in brain depends upon
two factors, a passive deposition due to enhanced
angiogenesis, leaky vasculature and restricted lymphatic
drainage as compared to normal tissue (Enhanced
Permeability and Retention or EPR) and active targeting of
moieties that are ligands for BBB or glioma receptors
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(lactoferrin and folate) since transport of molecules across
BBB is receptor mediated. Furthermore, data is present to
suggest promising potential in hitchhiking of NPs on blood
cells, preferably monocyte and macrophages, thereby
exploiting their abilities to circumvent biological
membranes.6
Current advances in NPs have generated a wide range of
both organic and inorganic NPs that are under
investigation for GBM treatment. These include liposomes,
polymeric NPs (PNP), lipid nanocarriers (LNC), metal
organic framework (MOF), porous silicon (pSi), EnGenIC
delivery vehicle(EDV™)  and mesoporous silica NPs (MPN)
to name a few. Each of these possess, and often share,
characteristics that grant certain merits and demerits. Most
possess the advantage of penetrating BBB, high drug
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Figure: MRI Brain with contrast (T1 weighted post gadolinium) images demonstrating a left frontal deep glioblastoma. Lesions like these are not suitable for gross total
resection due to their relationship with important eloquent areas. NPs delivering effective chemotherapy to such lesions would break new grounds in management.
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loading capacity, biocompatibility and the ability to convey
both hydrophilic and hydrophobic drugs.6,10 In particular,
liposome drug delivery systems, EDV™ and pSi are simple
and suitable for large scale production.6,10 Liposomes and
PNPs exhibit preferential accumulation of drugs in tumour
tissue.10 MOFs have adjustable structure and the potential
to act as adjuvant for radio-sensitization. Psi can not only
deliver multiple cargos, but also potentially limit GBM
invasiveness. High adsorptive properties and organized
pore framework of MSN address the issues with NP stability.
Moreover, their modifiable particle size, easily functionable
surfaces and ability to improve drug pharmacokinetics and
stability profile, shows promise to mitigate challenges
involved in drug delivery to the brain.6 PNPs improve
plasma circulation and half-life of drugs, hence, increase
bioavailability. LNCs require less raw material, are stable
and have a more sustained drug release.10
Most of these approaches are under pre-clinical or early
clinical trials for both in-vitro and in-vivo models. There are
still significant barriers that limit the utilization of NP based
drug delivery systems in treatment of GBM. Most significant
among these is the safety profile. Further concerns are
stability, regulatory mechanisms, variance of
pharmacodynamics among different individuals and need
for development of techniques to monitor drug
accumulation at target site.2,10 In view of constant
experiments, it is believed that in-depth knowledge of
mechanisms involved in diffusion kinetics of nanoparticles
along with cellular and molecular studies focused on
understanding GBM microenvironment, will provide crucial
information in the quest to design novel GBM specific
nanotherapeutics.10
Conclusion
Despite significant challenges, nanoparticle based drug
delivery systems are emerging as a promising field for the
treatment of glioblastomas. With numerous formulations
being tested, the choice of nanomaterial is an ongoing
debate which warrants extensive investigation with regard
to their biological and toxicological behaviour. Success
might still be a long way, but the application of NPs display
optimism to increase long term survival rates and possibly
revolutionise the treatment of GBM.
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